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Background: Today, the treatment of choice for high- and low-grade gliomas requires primarily surgical resection
to achieve the best survival and quality of life. Nevertheless, many gliomas within highly eloquent cortical regions,
e.g., insula, rolandic, and left perisylvian cortex, still do not undergo surgery because of the impending risk of
surgery-related deficits at some centers. However, pre and intraoperative brain mapping, intraoperative
neuromonitoring (IOM), and awake surgery increase safety, which allows resection of most of these tumors with a
considerably low rate of postoperatively new deficits.
Methods: Between 2006 and 2012, we resected 47 out of 51 supratentorial gliomas (92%), which were primarily
evaluated to be non-resectable during previous presentation at another neurosurgical department. Out of these, 25
were glioblastomas WHO grade IV (53%), 14 were anaplastic astrocytomas WHO grade III (30%), 7 were diffuse
astrocytomas WHO grade II (15%), and one was a pilocytic astrocytoma WHO grade I (2%). All data, including pre
and intraoperative brain mapping and monitoring (IOM) by motor evoked potentials (MEPs) were reviewed and
related to the postoperative outcome.
Results: Awake surgery was performed in 8 cases (17%). IOM was required in 38 cases (81%) and was stable in 18
cases (47%), whereas MEPs changed the surgical strategy in 10 cases (26%). Thereby, gross total resection was
achieved in 35 cases (74%). Postoperatively, 17 of 47 patients (36%) had a new motor or language deficit, which
remained permanent in 8.5% (4 patients). Progression-free follow-up was 11.3 months (range: 2 weeks –
64.5 months) and median survival was 14.8 months (range: 4 weeks – 20.5 months). Median Karnofsky Performance
Scale was 85 before and 80 after surgery).
Conclusions: In specialized centers, most highly eloquent gliomas are eligible for surgical resection with an
acceptable rate of surgery-related deficits; therefore, they should be referred to specialized centers.
Keywords: Language, Eloquent tumor, Rolandic region, Glioma, Neuromonitoring.Background
For the treatment of high- and low-grade gliomas,
surgery is an important part of a multimodal therapy [1-4].
Surgical tumor reduction has been shown to have a
impact on survival and quality of life and, thus, has to be
as extensive as possible [1,3-5]. Nonetheless, many
gliomas within highly eloquent regions, especially within* Correspondence: Sandro.Krieg@lrz.tum.de
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reproduction in any medium, provided the orthe insula, rolandic region, and the perisylvian cortex of
the dominant hemisphere, still frequently undergo limited
debulking or biopsy attributable to the supposed risk of
surgery-related deficits [6-9]. Resection of such highly
eloquent gliomas always involves a compromise between
the extent of resection and the preservation of motor or
language function. To achieve both goals, neurosurgeons
use multiple modalities to examine, visualize, and monitor
anatomy and function presurgically and during resection
[10-15]. By carefully choosing a multimodal setup includ-
ing preoperative mapping of motor and language functiond. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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intraoperative cortical and subcortical mapping using direct
cortical stimulation (DCS), intraoperative neuromonitoring
(IOM), and awake surgery, we can increase safety and,
therefore, allow resection of most such tumors with an
acceptable rate of postoperative new deficits [14-23].
Although the literature and data on eloquent glioma
surgery are broad, no studies or subgroup analyses are
at hand that analyzed the actual functional outcome and
oncological benefit of surgery in patients initially
diagnosed as inoperable. Thus, we present this retro-
spective analysis and evaluated all cases that presented
to our department for a second opinion. Neurological
course, preoperative nTMS, intraoperative DCS map-
ping, and IOM data were reviewed and related to new
postoperative deficits and postoperative imaging. More-
over, clinical outcomes were assessed during follow-up.
Methods
Patients
Between 2006 and 2012, we resected 47 out of 51
supratentorial gliomas, which were primarily judged to
be non-resectable during prior consultation at another
neurosurgical department. These departments were
European university departments or at least of university
level concerning the range and numbers of surgeries.
Four patients with glioma of the basal ganglia did not
undergo surgical resection but stereotactic biopsy. Dur-
ing this period between 2006 and 2012, 498 patients
underwent surgery of intracranial gliomas in our
department.
Decision for surgery was made during an interdis-
ciplinary conference including neurosurgeons, neuro-
oncologists, neuroradiologists, neuropathologists, and
radiation oncologists in all cases. An overview of all
patients is given in Table 1. In 9 out of these 47 cases
(19%), the tumor was located within or adjacent to the
precentral gyrus, in 15 cases (32%) within the insula, in
7 cases (15%) within the postcentral gyrus, in 3 cases
(6%) within the basal ganglia, in 5 cases (11%) within
the opercular inferior frontal gyrus, in 5 cases (11%)
within the middle superior temporal gyrus, and in 3
cases (6%) within the supramarginal gyrus. Mean tumor
diameter was 4.9 ± 2.6 cm (range 0.4 – 11.0 cm). Tumor
size was assessed on T2 FLAIR images for WHO grade
II and II and on T1 contrast-enhanced images for WHO
grade I and IV. A preoperative motor deficit was present
in 13 patients (28%). Median Karnofsky performance
scale (KPS) was 90 (range 40 – 100%). The mean age
was 47 ± 16 years (range 17 – 81 years); 19 patients
(40%) were female and 28 (60%) were male. Twenty-
seven tumors (59%) were in the dominant hemisphere.
Indication for awake surgery was a glioma within the left
insular and perisylvian region with sufficient remaininglanguage function to perform an intraoperative object
naming and counting task. Out of 47 cases, 25 were
glioblastomas WHO grade IV (53%), 14 were anaplastic
astrocytomas WHO grade III (30%), 7 were diffuse
astrocytomas WHO grade II (15%), and one was a
pilocytic astrocytoma WHO grade I (2%). As this report
wants to draw attention on the resectability of gliomas
per se, we also included this pilocytic astrocytoma in
our series because especially these tumors should
undergo resection.
Twenty-nine patients (62%) underwent surgery for
recurrent gliomas (grade II: 3 cases; grade III: 9 cases;
grade IV: 17 cases). Most common initial symptoms of
the patients were seizures in 22, paresis in 13, aphasia in
4, and hemihypesthesia in 2 cases.Preoperative evaluation
All patients underwent preoperative magnetic resonance
imaging (MRI) for tumor diagnosis, localization, preopera-
tive assessment, and for intraoperative neuronavigation
(BrainLAB Vector Vision 2W and BrainLAB Curve,
BrainLAB AG, Feldkirchen, Germany). Moreover, all
patients also received postoperative MR imaging to evalu-
ate the extent of the resection. In addition, every patient
was thoroughly examined before and after surgery
according to a standardized protocol including handed-
ness, muscle strength, coordination, sensory evaluation,
and cranial nerve function. Muscle strength was graded
for every muscle in accordance with the British Medical
Research Council Scale (BMRC) preoperatively, on the
first postoperative day, on the day of discharge, and during
postoperative follow-up. Language function was assessed
by the Aachen Aphasia Testing Battery preoperatively, at
the fifth postoperative day, and 3 and 6 months after
surgery [24].
The decision for the use of the different intraoperative
techniques such as ultrasound, neuronavigation, fiber
tracking, MEP monitoring, or awake surgery was done by
the operating surgeon depending on the specific tumor
location.Anesthesia
As volatile anesthetics have been shown to severely
interfere with IOM, we used total intravenous
anesthesia in all cases without exception and strictly
avoided the use of volatile anesthetics before and during
surgery [25-27]. Thus, anesthesia was induced and
maintained by continuous propofol administration, and
intraoperative analgesia was achieved through continu-
ous administration of remifentanyl. Neuromuscular
blocking was avoided during surgery and only used for
intubation by rocuronium.





























1 III Y 11.0 Y Y N N N N 90 90 GTR N
2 III N 5.1 N N N T N T 70 60 GTR Y
3 III Y 6.8 Y N Y N N N 70 70 GTR N
4 III Y 10.8 N N N T N N 90 70 GTR N
5 IV Y 9.2 Y N Y N N T 80 80 STR Y
6 IV N 4.5 N N N N N T 70 70 GTR Y
7 IV Y 1.9 Y Y N T N N 80 60 STR N
8 IV Y 0.4 Y Y N N N N 100 100 STR N
9 IV Y 4.5 Y Y Y T N N 90 90 GTR N
10 IV N 5.6 Y N N N N N 90 90 GTR N
11 II Y 5.1 N N N N N N 90 90 GTR Y
12 III Y 4.5 Y N N N N N 100 100 GTR N
13 II N 7.9 Y N Y T N T 70 70 GTR Y
14 II N 6.1 N N N N N N 100 100 GTR N
15 IV Y 3.0 Y Y N N N N 100 100 GTR N
16 III Y 6.4 N N N N N N 100 100 GTR N
17 IV Y 7.0 Y Y N T N N 70 30 GTR N
18 III Y 0.7 Y N N T N N 100 80 GTR N
19 III N 9.3 N Y N N N N 100 100 GTR N
20 II Y 4.6 Y N N T N T 100 90 GTR Y
21 IV Y 2.6 Y Y N T N N 50 50 GTR N
22 IV Y 2.0 Y Seed Y P N P 80 70 STR Y
23 IV Y 4.9 Y Y N N N N 90 80 GTR N
24 IV N 6.8 Y N Y N N N 70 70 STR N
25 II N 5.6 N N N N N N 70 70 STR N
26 IV Y 2.9 Y Y Y N N N 70 70 GTR N
27 IV N 4.6 N N N N N N 90 90 GTR N
28 III Y 4.0 Y N Y P N N 90 50 GTR N
29 IV Y 6.0 Y Y N N N N 80 80 GTR N
30 III N 10.0 Y N N N N N 90 90 STR N
31 III N 5.3 Y Y N N N N 90 90 GTR N
32 IV N 3.3 N Y Y N N N 40 40 STR N
33 III N 4.0 Y N N N N T 90 90 STR Y
34 II Y 1.5 N N N N N N 100 100 GTR N
35 III Y 1.1 Y N N P N N 90 40 GTR N
36 IV Y 6.0 N N N N N N 90 90 GTR N
37 IV Y 1.4 Y Y N T N N 100 50 GTR N
38 III Y 7.1 Y N N T N N 100 60 STR N
39 I N 1.5 N N Y N N N 50 100 GTR N
40 IV Y 2.4 Y Y Y T N N 60 50 GTR N
41 IV N 6.0 Y Y N N N N 100 100 GTR N
42 IV Y 5.6 Y Y N N N N 90 90 GTR N
43 IV N 4.5 Y Y Y N N N 50 50 GTR N
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Table 1 Patient characteristics (Continued)
44 IV Y 4.9 Y Y N P N N 90 80 GTR N
45 IV Y 5.0 Y Y N N N N 90 90 GTR N
46 IV N 4.5 Y Y Y T N N 80 70 STR N
47 II N 2.0 Y N N T N N 100 80 STR N
Patient characteristics of the 47 patients, which underwent surgical resection. Tumor diameter (in cm), preoperative deficit, postoperative deficit (T = temporary,
P = permanent, N = no deficit), and Karnofsky Performance Scale (KPS) are outlined. Y = yes, N = no. TMZ = Temozolomide. RTx = radiotherapy. EOR = extent of
resection. STR = subtotal resection. GTR = gross total resection.
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Positron emission tomography (PET) images were fused
with continuous sagittal images of T1-weighted 3D
gradient echo sequence, T2 FLAIR, and DTI data. In 11
patients (23%), nTMS was also used to map cortical
language and motor areas preoperatively; nTMS data
were then fused into the neuronavigation dataset.
Finally, data were transmitted to the neuronavigation
system (BrainLAB Vector Vision 2W and BrainLAB
CurveW, BrainLAB AG, Feldkirchen, Germany), as
previously described [13,14].
Intraoperative MEP monitoring
IOM by direct cortical stimulation was used in 38 of 47
cases (81%). Subsequent to craniotomy and durotomy,
a strip electrode with eight contacts (ADTechW strip
electrode, AD Technic, City, WI, USA or Inomed
Medizintechnik, Emmendingen, Germany) was positioned
subdurally onto the cortex of the rolandic region. An
angle of 60 − 70° to the supposed central sulcus was aimed
at. After positioning the strip electrode, the median nerve
was stimulated and the central sulcus was identified by
somatosensory evoked potential phase reversal [28]. DCS
mapping of the motor cortex was then performed with
intensities between 5 and 14 mA, square-wave pulse with
duration of 0.2 – 0.3 ms, frequency of 350 Hz, and a train
of 5 pulses as previously reported [15,28,29]. To stimulate
motor evoked potential (MEP) monitoring of the upper
and lower extremity, square-wave pulses with duration of
200–700 μs, a frequency of 350 Hz, and a train of 5 pulses
were applied. The used protocol was published previously
[15]. Decline in amplitude of more than 50%, which was
not explained by technical issues, was considered a con-
siderable deterioration and was reported to the surgeon. If
changes of compound muscle action potential (CMAP)
occurred, the event was instantly reported to the neuro-
surgeon, who reversed the causative maneuver, if possible.
Partial loss of CMAP from related muscle groups was
regarded as a decline rather than a loss. Latency increases
devoid of concomitant deterioration of amplitude rarely
occurred.
Awake monitoring
Awake surgery was only performed when the tumor was
within the left insula, operculum, dorsal superior temporalgyrus, angular gyrus, and supramarginal gyrus. Tumors
within the left pre- or postcentral gyrus were not operated
by awake surgery. The day before surgery, a neuro-
psychologist trained the patient for the object naming task
and baseline testing of all pictures was performed. Only
pictures that were named fluently were included for
intraoperative mapping. In surgery, the patient was
positioned supine and 45° to the right side. Before sharp
fixation of the head, regional anesthesia was applied to the
galea by bupivacaine. Fifteen minutes before language
mapping, propofol infusion was stopped and remifentanyl
was progressively reduced to achieve an optimum level of
analgesia during mapping. DCS mapping was performed
using bipolar stimulation every 5 mm using 3 to 15 mA
over 4 seconds and a 60 Hz technique. To detect
afterdischarges, a direct cortical electroencephalogram
was recorded with 8 channels. During mapping, pictures
of common objects were presented to the patient in a
time-locked way, and elicited speech impairment was
evaluated by the neuropsychologist. The patient had to
name the object and start every naming with the sentence
“This is. . .” Positive sites were marked at the cortical
surface with numbers indicating the evoked disturbance.
After completion of cortical mapping, the resection was
performed under continuous language testing to also
monitor affection of subcortical fiber tracts. After resec-
tion, the patient was then sedated during wound closure.
Tumor resection
An ultrasound aspirator (Sonopet Ultrasonic Aspirator,
Stryker Medical, Portage, MI, USA) as well as neuro-
navigation was used for all cases. Upon any amplitude
loss or decline of more than 50% of the initial MEP
amplitude in at least one channel, resection was halted,
spatulas removed, and the surgical field was irrigated
with warm Ringer’s solution. The MEP technique is exten-
sively described above (Intraoperative MEP monitoring).
In cases of awake surgery, resection was immediately
stopped whenever the neuropsychologist reported
deterioration of language function. In cases of resection
close to a major vasculature, the surgical field was
irrigated with nimodipine to reverse potential vaso-
spasm. After renormalization/stabilization of MEPs,
resection was continued. If potentials did not recover,
resection was stopped at this tumor region.
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For every patient, neurological status was directly
assessed after surgery, 6–8 weeks postoperatively and
during follow-up on a regular basis every 3–12 months,
depending on the tumor entity. Moreover, each patient
underwent an MRI scan within 48 hours after operation.
During follow-up, MRI scans were also performed every
3–12 months depending on the tumor grade. Thus, we
evaluated the MRI scan of the first postoperative day
with regard to the extent of the resection, increasing
edema, diffusion impairment, and bleeding to find
explanations for neurological deterioration without
intraoperatively MEP changes. Extent of resection was
defined as gross total resection (GTR) or subtotal resec-
tion depending on the presence of residual tumor on T2
FLAIR (WHO grade II and III) or T1 contrast-enhanced
sequences (WHO grade I and IV). Furthermore, we
evaluated every MRI scan during follow-up for recur-
rent tumors. Neurological status in this study was only
considered during progression-free survival. New
postoperative neurological motor deficit was distin-
guished between temporary and permanent deficit.
Temporary deficit was defined as a new or aggravated
postoperative motor deficit that disappeared at least
until the 6- to 8-week follow-up. Permanent deficit was
defined as new or aggravated postoperative motor
deficit that did not resolve during follow-up.
Ethical standard
The study is well in accordance with the ethical
standards of the Technical University of Munich, the
local ethics committee (registration number: 2826/10),
and the Declaration of Helsinki.
Statistical analysis
To test the distribution of several attributes, a chi-square
or Fisher Exact test was performed. Differences betweenFigure 1 Illustrative case of gross total resection of a left-sided insulagroups were tested using the Kruskall-Wallis test for
nonparametric one-way analysis of variance (ANOVA),
followed by Dunn’s test as the post hoc test. Differences
between two groups were tested using the Mann–Whitney-
Wilcoxon test for multiple comparisons on ranks for inde-
pendent samples, followed by Dunn’s test as the post hoc
test. All results are presented as mean ± standard deviation
(SD). Median and range were also delivered (GraphPad
Prism 5.0 c, La Jolla, CA, USA); p < 0.05 was considered
significant.Results
GTR was achieved in 35 cases (74%) (Figure 1). Awake
surgery was performed in 8 cases (17%), whereas 38 cases
(81%) were performed under continuous MEP monitoring.
Three cases (6%) received awake craniotomy and MEP
monitoring for subcortical dissection within the pyramidal
tract after the awake phase. Thus, 4 cases underwent
surgery without MEP or awake monitoring. For evaluation
and follow-up of neurological function, we only considered
neurological status during progression-free survival, which
was 11.3 months (range: 2 weeks – 64.5 months) and
median overall survival was 14.8 months (range: 4 weeks –
20.5 months) depending on recurrence and malignancy
(Table 2). Before surgery, not only recurrent but also some
newly diagnosed gliomas were treated using chemo- or
radiotherapy. Table 3 provides an overview. Moreover, there
were no healing problems or postoperative infections in the
patients within this cohort.Preoperative functional mapping
Navigated TMS was used for preoperative mapping of
language areas in 4 cases and motor areas in 6 cases be-
cause 2 cases underwent combined motor and language
mapping.r glioma WHO grade 3.





primary recurrent primary recurrent
WHO grade I 47.9 - alive -
WHO grade II 38.3 26.0 all alive all alive
WHO grade III 21.6 22.0 all alive 20.5
WHO grade IV 8.6 7.9 5.1 6.0
Columns 2 & 3: mean follow-up for alive patients. Columns 4 & 5: overall
survival of deceased patients. This series only contains one patient with
initially diagnosed WHO grade I glioma. When patients are alive, mean overall
survival equals to mean follow-up.
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Neuronavigation was applied in all cases. Diffusion
tensor imaging fiber tracking was included in 18 (38%);
fluorescence guidance using 5-aminolevulinic acid was
applied in 18 (38%); and intraoperative ultrasound was
used in 1 case.
Awake craniotomy
Of patients undergoing awake surgery, 5 patients (63%)
suffered from initially diagnosed and 3 patients (37%)
suffered from recurrent glioma. After awake craniotomy
on 8 patients, 6 patients (75%) showed a new aphasia at
the first postoperative day but only 1 patient (13%)
experienced a permanent surgery-related aggravated
aphasia during long-term follow-up. GTR was possible
in 5 cases (63%).
Correlation of tumor type and location to postoperative
motor deficit
Postoperative temporary or permanent impairment of
motor function was significantly higher in recurrent
tumors: After primary glioma resection (18 patients), no
patients showed any permanent deficit, whereas 4
patients (22%) presented with temporary and 14 patients
(78%) with no new postoperative motor deficit. However,
after resection of recurrent glioma (28 patients), 4
patients (14%) showed permanent and 10 patients (34%)
showed temporary surgery-related new paresis. Thus, 15
patients (52%) showed no new motor deficit (Figure 2).Table 3 Presurgical therapy
Primary surgery Recurrent tumor
cases % cases %
RTx only 2 11 0 0
TMZ only 6 33 8 28
TMZ + RTx 0 0 2 7
Seed 0 0 1 3
An overview on presurgical chemo- or radiotherapy in patients with recurrent
but also with initially diagnosed gliomas, after which non-resectability was
noted. Temozolomide (TMZ) and radiotherapy (RTx) were also
applied combined.As expected, postoperative temporary and permanent
impairment of motor function were related to tumor
location with no respect to initial or recurrent tumor.
After resection of gliomas in the precentral gyrus, 11%
of all patients (1 patients) experienced permanent
deterioration of motor function. Additionally, 44% of
patients (4 patients) with a precentral glioma showed a
temporary motor function deficit. After resection of
insular gliomas, patients showed temporary deficit in
33% (5 patients) and permanent deficit in 7% of all cases
(1 patient). Patients with gliomas affecting the subcor-
tical white matter temporarily deteriorated in 67%
(2 patients) and permanently deteriorated in 33%
(1 patient) of cases with regard to motor function.
MEP monitoring
In all intended 38 cases, IOM through continuous MEP
monitoring was possible. MEPs were stable throughout
the operation in 18 patients (47%), showed reversible
amplitude decline of more than 50% baseline but
recovered in 15 patients (39%), and irreversible ampli-
tude declined more than 50% baseline in 5 patients
(13%). Postoperatively, 18 patients (39%) had a new
motor deficit, which remained permanent in 4 patients
(8.5%). Irreversible MEP decline was only observed in
WHO grade III and grade IV gliomas, but no other
significant difference existed with respect to the differ-
ent tumor types (data not shown). Out of those 20 cases
(52%) with MEP amplitude decline, resection was
temporarily stopped, attributable to IOM in 10 cases
(26% of all 38 IOM cases) and completely halted in 6 of
these cases (16% of all 38 IOM cases). Immediately after
MEP decline, retractors were repositioned and the
resection cavity was additionally irrigated. In 5 of these
10 cases (50%), STR was achieved, whereas STR was
performed in only 3 out of 28 cases (11%), which were
not influenced by IOM due to stable amplitudes
(p = 0.0186; Figure 3). Postoperative new temporary or
permanent motor deficits were similar in the STR
(unchanged: 58%, temporary: 33%, permanent: 9% of 12
cases) and GTR groups (unchanged: 63%, temporary:
28%, permanent: 9% of 35 cases) (Figure 4). In contrast,
in those 10 cases in which the surgeon had to stop
resection because of considerable MEP decline, we
recognized an unchanged motor function in 30% of
cases and a new temporary deficit in 60% of cases, and
new permanent motor deficit in 10% of cases. Without
the influence of IOM, motor function was unchanged in
68% of cases, temporarily deteriorated in 21% of cases,
and permanently deteriorated in 11% of cases (p = 0.07;
Figure 5). Although the data failed to show statistical
significance, they showed a trend toward a higher rate
of temporary motor deficit in patients in which resec-
tion was limited by IOM.
Figure 2 Recurrent glioma. Postoperative impairment of motor function is higher after resection of recurrent tumors compared to gliomas
undergoing initial resection (p < 0.01185).
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To find sufficient basis for the explanation of postoperative
neurological deterioration, we evaluated all postoperative
MRI scans. Nine patients (13%) had temporary new
motor deficit despite recovered MEP decline in which
MRI revealed increasing edema in 4 cases and second-
ary hemorrhage within the resection cavity in 5 cases.
However, only 3 out of these 5 cases were symptomatic
and underwent revision surgery at the same day. Out of
those 4 patients with new permanent surgery-related
paresis, 2 presented with ischemic lesions at the border
of the resection cavity and 2 showed resection within
motor eloquent regions. With regard to the 8 awake
cases, 2 patients showed temporarily and 1 patientFigure 3 Influence of IOM on the extent of resection. When
surgery was influenced by IOM due to MEP amplitude decline of
more than 50% baseline, gross total resection (GTR) was only
achieved in 50% of cases, whereas GTR was achieved in 89% of
cases in which IOM showed no impact on surgery due to stable
amplitudes (p0.0186).presented with permanently deteriorated language func-
tion. All 3 cases were glioblastoma multiforme within
the angular gyrus and postoperative MRI showed no
edema, hemorrhage, or ischemia.
Operation on recurrent gliomas
In this series, we operated on 29 recurrent gliomas.
Three were WHO grade II, 9 were WHO grade III, and
17 were glioblastoma (GBM). Of these patients, 7 (24%)
already had preoperative paresis. Four patients were
operated awake and one of these patients (25%) suffered
from preoperative aphasia. However, continuous MEP
monitoring was possible in all 24 intended cases (83%).
Compared with the first operation, resection of recur-
rent gliomas showed a lower degree of subtotal
resections but without reaching statistical significance
(17% in recurrent and 39% in the first operation).
Concerning resections of recurrent glioma, postoperative
new permanent deficits were observed in 14% of all
cases (4 patients) (aphasia: 3%, paresis: 11%), whereas
temporary deficits occurred in 35% of cases (10 cases)
(aphasia: 10%, paresis: 25%) (Figure 2). Pre- as well as
postoperative KPS was also comparable in patients who
underwent the first (before: 85, after surgery: 90) and
repeated resection (before: 85, after surgery: 80).
Discussion
During the last decade, surgical resection became in-
creasingly important as part of a multimodal therapeutic
regime for the treatment of high- and low-grade gliomas
[1,4,23,30,31]. However, even today, many gliomas
within highly eloquent cortical regions still regularly
undergo only debulking or biopsy. The most striking
argument for this approach is the risk of surgery-related
Figure 4 Extent of resection vs. postoperative paresis. Postoperative new temporary or permanent motor deficits were highly comparable in
patients with subtotal (STR) and gross total (GTR) resection.
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data on surgery on eloquent gliomas, the risk of new neuro-
logical deficits seems moderate [15,18,22,23,31-33]. Espe-
cially when a multimodal and function-guided approach is
used [34]. Yet, no studies or subgroup analyses exist that
reviewed the actual functional outcomes and oncological
benefits of surgery in patients initially diagnosed as
inoperable.
In our series, only 8.5% of all patients with gliomas in
or adjacent to eloquent motor areas suffered from new
permanent deterioration of motor function after surgery
(Figure 2). Regarding these data, our study is well inFigure 5 IOM vs. postoperative paresis. When surgery was influenced b
showed a trend towards a higher rate of temporary motor deficit compareaccordance with previous studies [26,35,36]. When also
considering the high postoperative KPS in initially
diagnosed and recurrent gliomas, we have to strongly
reject the argument that these patients have an
unacceptable high risk of surgery-related disability or
loss in quality of life.
With regard to the GBM subgroup, median survival
was comparable to the non-surgical series; however, KPS
was higher in our patients even after surgery. Thus,
high-quality survival was improved (Table 2) [7-9,37].
Concerning the impact of the extent of resection on
the actual survival the subgroups of this study are toy IOM due to MEP amplitude decline of more than 50% baseline data
d to patients in which resection was not affected by IOM (p = 0.07).
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to be considered as a pilot study.
Preoperative functional mapping
As also reported previously, we observed an important
impact from preoperative nTMS mapping of the motor
eloquent cortex [14,38]. Moreover, 4 additional patients
underwent nTMS mapping of the language eloquent
cortex. Although nTMS language mapping still requires
further research, it is already a valuable tool in a multi-
modal approach [39,40].
Correlation of tumor type and location to postoperative
motor deficit
In our series, most tumors were located within the
insula, rolandic region, or the perisylvian cortex. When
analyzing our data, we were not able to show any
statistically significant difference for the risk of surgery-
related new motor deficit with regard to tumor location.
Thus, we cannot identify any of these structures to be
less eligible for surgical resection, which is well in
accordance with previous findings [15]. However, we
must emphasize that surgery of recurrent glioma has a
significantly higher risk of surgery-related new motor
deficit (Figure 2), which was also found by others and
has to be kept in mind when advising our patients
[15,41]. The reasons for this phenomenon are supposed
to be primarily vascular. As primary resection of these
gliomas usually reaches the borders of motor or
language eloquent regions, recurrent tumor growth
invades this eloquent brain tissue and its supplying
arteries. Thus, our series showed that surgery of recur-
rent gliomas causes a higher rate of ischemia adjacent
to the resection cavity as initial surgery does, which is
contradictive to previous studies [41]. Moreover,
chemotherapy as well as radiation therapy might alter
neuronal and vascular metabolism and therefore impair
motor plasticity as it has been described recently [42].
MEP monitoring
MEP amplitude decline caused a significantly higher
rate of STR (Figure 3). However, this group also showed
a lower rate of temporary but not of permanent new
motor deficits (Figure 4). However, this result seems
to mostly come from the small number of cases (10
patients) in which surgery was influenced by IOM.
Without the influence of IOM on motor function, we
failed to show statistical significance. However, the data
showed a trend toward a higher rate of temporary
motor deficit in patients in which resection was limited
by IOM. Yet, the rate of permanent motor deficits
was identical (Figure 5). These findings have to be
interpreted as a result of the small group of patients
with influence of IOM on the course of surgery (10patients) because larger series indeed showed an influ-
ence of IOM on the functional outcome of long-term
follow-up [15,17].
Concerning those 2 cases of reversible MEP decline
with permanently new motor deficit, in which we
observed partial removal of the primary motor cortex
we have to state that this partial resection of rolandic
cortex is not the only explanation although it is the only
explanation, which can be observed on postoperative
MRI. A dislocation of the cortical MEP electrode and
replacement to another cortical muscle representation is
also an explanation that has to be mentioned.
Recurrent gliomas
In this series, we operated on 29 recurrent gliomas.
Compared with the first operation, resection of recurrent
gliomas showed a surprisingly lower degree of STR but
without reaching statistical significance (17% in recurrent
and 39% in the first operation). However, a higher rate of
very relevant postoperatively new permanent deficits was
observed (aphasia: 3%; paresis: 11%; see Figure 2). None-
theless, pre and postoperative KPS was also comparable in
patients who underwent the first and repeated resection,
which shows a persistent quality of life. In particular, our
data on potential survival rates offers further evidence that
reoperation of recurrent high-grade gliomas is beneficial.
Although some authors stated that a second surgery for
high-grade gliomas is comparable to conservative treat-
ment [43], others provided evidence that surgery improves
survival and quality of life in most patients [44].
Moreover, as mentioned in Table 3, only 2 patients
with recurrent gliomas underwent both chemo- and
radiotherapy as initial treatment. With regard to the
supposed standardization of glioma therapy, this number is
rather small and shows us that even more standardization
or even centralized and not only interdisciplinary neuro-
oncological tumor conferences might be indicated.
Conclusions
Our results showed that gliomas judged as non-resectable
are potentially eligible for surgical resection. By using a
multimodal approach including preoperative functional
mapping, IOM, and awake craniotomy in some cases,
achieving a high extent of resection at an acceptable rate
of postoperative neurological deterioration is possible.
Particularly after primary resection, no patient in our
series suffered from any new permanent deficit. With
regard to this data, patients with primarily rated
“inoperable” gliomas should be referred to a specialized
center to achieve the best oncological basis by surgical
resection for an adjuvant therapy. Although the rate of
new surgery-related neurological deficits is low and
postoperative KPS and survival advocates for a surgical
approach in the vast majority of cases, this decision
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the context of a neuro-oncological conference including
neurosurgical, neurologists, neuroradiologists, and radio-
therapist. Moreover, neurosurgical centers with limited ex-
pertise on surgery of such highly eloquent lesions should
strongly refer their patients for a second opinion to a
specialized center.
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